1. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
- Author
-
Lin GN, Peng JW, Liu PP, Liu DY, Xiao JJ, and Chen XQ
- Subjects
- Aged, Carcinoma, Non-Small-Cell Lung pathology, Erlotinib Hydrochloride adverse effects, Female, Gefitinib, Humans, Lung Neoplasms pathology, Male, Predictive Value of Tests, Prognosis, Protein Kinase Inhibitors adverse effects, Quinazolines adverse effects, Survival Analysis, Treatment Outcome, Carcinoma, Non-Small-Cell Lung blood, Carcinoma, Non-Small-Cell Lung drug therapy, Erlotinib Hydrochloride therapeutic use, Lung Neoplasms blood, Lung Neoplasms drug therapy, Lymphocytes pathology, Neutrophils pathology, Protein Kinase Inhibitors therapeutic use, Quinazolines therapeutic use
- Abstract
Aim: Elevated neutrophil-to-lymphocyte ratio (NLR) has been demonstrated to be a poor prognostic factor in multiple types of malignancies, whereas the effect of NLR on the prognosis of epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients treated with first-line EGFR tyrosine kinase inhibitors (TKIs) is not fully addressed., Methods: 81 metastatic NSCLC patients harboring EGFR mutation treated with first-line EGFR TKIs were retrospectively included. The associations between baseline clinical characteristics, including NLR, and tumor response, progression and survival were investigated., Results: Elevated NLR (≥3.5) was observed in 33 of 81 patients. The progression-free and overall survival of the patients with increased NLR was significantly worse than that of the patients with decreased NLR (8.20 vs 10.60 months, P < 0.001 and 17.20 vs 23.20 months, P < 0.001, respectively). Elevated NLR was confirmed to be an independent prognostic factor for worse progression-free and overall survival in Cox multivariate analysis., Conclusion: Elevated NLR is likely to be associated with poor outcome in EGFR-mutated advanced NSCLC patients treated with first-line EGFR TKIs., (© 2014 Wiley Publishing Asia Pty Ltd.)
- Published
- 2017
- Full Text
- View/download PDF